Your browser doesn't support javascript.
loading
Intranasal delivery of experimental compounds in orthotopic brain tumor mouse models.
Eyme, Katharina M; Carvalho, Litia; Badr, Christian E.
Affiliation
  • Eyme KM; Department of Neurology, Massachusetts General Hospital, Boston, MA 02129, USA.
  • Carvalho L; Department of Neurology, Massachusetts General Hospital, Boston, MA 02129, USA.
  • Badr CE; Neuroscience Program, Harvard Medical School, Boston, MA, USA.
STAR Protoc ; 2(1): 100290, 2021 03 19.
Article in En | MEDLINE | ID: mdl-33532737
Effective therapeutics for malignant primary brain tumors, such as glioblastomas (GBMs), are urgently needed. To facilitate and expedite early-phase GBM therapeutic development, we describe a protocol that allows the intranasal delivery of experimental compounds in GBM orthotopic mouse models. Compounds delivered through this route can bypass the blood-brain barrier and thus help validate effective therapeutic targets for GBMs. For complete details on the use and execution of this protocol, please refer to Pinkham et al. (2019).
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Brain Neoplasms / Glioma / Neoplasms, Experimental Type of study: Guideline Limits: Animals / Humans Language: En Journal: STAR Protoc Year: 2021 Type: Article Affiliation country: United States

Full text: 1 Database: MEDLINE Main subject: Brain Neoplasms / Glioma / Neoplasms, Experimental Type of study: Guideline Limits: Animals / Humans Language: En Journal: STAR Protoc Year: 2021 Type: Article Affiliation country: United States